Singapore, 7 March 2016 - Ferring Pharmaceuticals today announced the inauguration of their new Asia Pacific headquarters at Capital Tower in Singapore. The new headquarters will have strategic oversight and executive management responsibilities over the company’s regional entities and activities in Asia Pacific – a region identified for fast growth and future development and investment by Ferring Pharmaceuticals.
The new Ferring Asia-Pacific Regional Headquarters focuses on supply chain planning and coordination to support the growth of emerging markets in Asia with central functions
The new Ferring Asia-Pacific Regional Headquarters will facilitate collaboration across various operational disciplines and will see functions such as supply chain planning and coordination, intellectual property management, IT, business development and planning, sales and marketing, regulatory and medical affairs coming together to support the Asia Pacific countries where Ferring operates. The Company aims to establish an agile supply chain with local packaging activities that will support the growth of its Asia Pacific countries. Singapore’s strategic location allows Ferring to respond faster to customers’ needs as customer service and support can be provided in the same time zone now, potentially reducing supply lead time by up to 2 months.
Ferring Asia Pacific will have opportunities for professionals operational in the above fields and will open with around 45 employees. Ferring expects that significantly more than ¾ of these employees will come directly from Singapore
“Asia Pacific is the fastest-growing region for the company and this is just the start of an exciting journey of growth to come,” said Michel Pettigrew, COO and President of Ferring Pharmaceuticals (Ferring Group). “Singapore is a leading logistics hub globally and has world-class intellectual property protection. It is also Asia’s fastest-growing bio cluster, presenting strategic partnership opportunities with research institutions, corporate labs and hospitals to develop new medicines and future therapies that can be customised for regional and global markets.”
“Ferring’s vote of confidence in Singapore is testimony to our value as a leading hub with strong connectivity to the region, where companies can drive their business growth from Singapore. We warmly welcome Ferring’s decision to leverage Singapore’s innovation ecosystem to develop brands and products for markets and customers in Asia-Pacific and beyond”, said Ms. Ho Weng Si, Deputy Director of Biomedical Sciences, Singapore Economic Development Board.
Ferring Asia-Pacific Regional Headquarters commits S$10mil over five years for R&D in several therapeutic areas, including female healthcare
Ferring is keen to establish partnerships with hospitals, research institutions and universities to conduct R&D in the company’s prioritised disease areas and those of relevance to the Asia Pacific markets. Ferring is a world leader in novel peptide-based drugs and biotechnology derived medicines, such as recombinant proteins and other biologics.
“Ferring aspires to progress in our prioritised disease areas including infertility, obstetrics, gastroenterology and urology, by focusing our resources on the most productive projects delivering appropriate solutions to patients. Our desire is to get closer to our markets to better meet the needs of patients in these geographies,” said Alex Chang, Senior Vice President Asia Pacific, Ferring Asia-Pacific Regional Headquarters.
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in 60 countries and markets its products in 110 countries.To learn more about Ferring or its products please visit www.ferring.com.
For further information:
HP: 9823 7722